Living With Sickle Cell Disease in the COVID-19 Pandemic

Pain Clinical Trial

Official title:

A Longitudinal Survey Study on Living With Sickle Cell Disease in the COVID-19 Pandemic

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04417673
• Other study ID #: 999920125
• Secondary ID: 20-HG-N125
• Status: Completed
• Start date: June 15, 2020
• Est. completion date: May 18, 2022

Study information

• Verified date: January 9, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Background: Sickle cell disease (SCD) is a chronic illness. It affects about 100,000 people in the United States. People with SCD have red blood cells that are sickle-shaped and impaired in their function. This results in a lifetime of complications that affect every organ system. People with SCD also are at greater risk for respiratory infections and lung problems. Researchers want to study how this population s stress, anxiety, fear, pain, sleep, and health care use are being affected by the COVID-19 pandemic. Objective: To study the extent and impact of life changes induced by the COVID-19 pandemic on people living with SCD in the U.S. Eligibility: People age 18 and older with SCD who live in the U.S. Design: Participants will complete a survey online. The questions will focus on the following: Medical history Mental and physical health Demographics Stress Resilience Health care use COVID-19 Beliefs about medical mistrust and participation in research. At the end of the survey, participants will be asked if they would like to take the survey again in the future. If they reply "yes," then they will be contacted by the study team in 6-9 months to take the survey again. They may complete the survey again in 6-8 months, 12-15 months, and 18-21 months. The survey should take less than 40 minutes to complete. Participants' data will be coded to protect their privacy. The coded data may be shared with other researchers.

Description:

Study Description: Longitudinal online survey of adults living with sickle cell disease (SCD) in the United States. The objective of the study is to examine the extent and impact of life changes induced by the COVID-19 pandemic on individuals living with SCD. It is our hypotheses that adults living with SCD will be adversely impacted by COVID-19 in terms of stress, anxiety, coping and sleep. Individuals living with SCD will have higher fear, isolation, anxiety and stress if they have higher clinical severity. In-person healthcare utilization for individuals with SCD will be reduced during the COVID-19 pandemic. Virtual healthcare utilization will increase for SCD individuals but satisfaction with healthcare quality will decrease. Objectives: Primary Objective: The primary objective of the study is to examine the extent and impact of life changes induced by the COVID-19 pandemic on individuals living with sickle cell disease (SCD). These objectives are: (1) To assess how the COVID-19 pandemic affects the psychological well-being of individuals living with SCD; (2) To examine the association between clinical severity of SCD and an individual s response to the COVID-19 pandemic; (3) To investigate whether news and other media consumption during the COVID-19 pandemic influence individual psychological well-being; (4) To determine the extent of COVID-19 induced trauma in individuals living with SCD, and its effect on health behaviors and psychological well-being; (5) To investigate the impact of the COVID-19 pandemic on healthcare utilization for SCD individuals. Secondary Objectives: Our secondary objectives broadly examine the attitudes and viewpoints of individuals with SCD on issues of trust and the future of medical advancements for COVID-19 treatment(s). These will be examined in conjunction with the primary objectives and are: (1) To examine the role that medical and government mistrust may have on the experiences and behaviors of individuals with SCD during the pandemic; (2) To assess community attitudes towards clinical trials for COVID-19. Endpoints: The endpoints for the study are divided into psychosocial measures as well as physical measures and are: (1) Stress; (2) Anxiety; (3) Depressive symptomology; (4) Sleep; (5) Pain episodes and clinical severity; (6) Healthcare utilization (primary care, emergency department, telemedicine, other). The secondary endpoint is an examination of the receptivity of SCD individuals to future health recommendations and medical treatment(s). Study Population: Sample up to 1000 adults living with SCD in the United States, 18 years of age or older. Description of Sites/Facilities Enrolling Participants: Two cohorts will be recruited for this study: (1) Participants in the INSIGHTS study (NCT02156102) (2) Participants recruited by Sickle Cell 101 and/or from the NIH Study (NCT01633021), and/or from other advocacy groups or doctor s offices. Sickle Cell 101 (SC101) is a Silicon Valley-based non-profit organization that specializes in sickle cell education for the patients, caregivers, healthcare professionals, and other key stakeholders affected by sickle cell disease and trait globally. Study Duration: Proposed enrollment opening June 1, 2020 - proposed end of data analyses from fourth wave of the study June 2022. Participant Duration: Each participant will be invited to take the online survey every six-nine months for four data collection periods. Each survey will last 30-45 minutes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: May 18, 2022
• Est. primary completion date: May 18, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

• INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the

following criteria:

1. Stated willingness to comply with all study procedures and availability for the duration of the study

2. Adults, aged 18 years or older, of any race, sex, gender, ethnicity, and/or nationality

3. Sickle Cell Disease, any genotype

4. Current Resident of the United States EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation

in this study:

1. Minors less than 18 years of age

2. Adults with Sickle Cell Trait, Beta Thalassemia, Alpha Thalassemia or any blood disorder other than Sickle Cell Disorder

3. Adults who lack access to the Internet

4. Live outside the United States (unless they are from the INSIGHTS Study)

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Anxiety
• COVID-19
• Health Care Utilization
• Isolation
• Pain
• Sickle Cell Disease

Locations

Country	Name	City	State
United States	National Human Genome Research Institute (NHGRI)	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Human Genome Research Institute (NHGRI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020 Jun;189(5):851-852. doi: 10.1111/bjh.16734. Epub 2020 May 8. No abstract available. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stress	We will examine how the COVID-19 pandemic impacts stress levels among individuals with sickle cell disease (SCD).	BASELINE, MONTH 6, MONTH 12, MONTH 18
Primary	Pain episodes, and severity	We will examine the association between clinical severity of SCD and an individual s response to the COVID-19 pandemic.	BASELINE, MONTH 6, MONTH 12, MONTH 18
Primary	Healthcare utilization (primary care, emergency department, telehealth other)	We will investigate the impact of the COVID-19 pandemic on healthcare utilization for SCD individuals.	BASELINE, MONTH 6, MONTH 12, MONTH 18
Primary	Depressive symptomology	This is an examination of questions relating to depression, which we will examine within our cohort.	BASELINE, MONTH 6, MONTH 12, MONTH 18
Primary	Anxiety	We will examine how the COVID-19 pandemic impacts anxiety levels among individuals with SCD.	BASELINE, MONTH 6, MONTH 12, MONTH 18
Secondary	Receptivity to future health recommendations and medical treatment(s).	We would like to explore how the attitudes about treatment and levels of trust will serve as mediating factors for the experiences of individuals with SCD during this pandemic.	Baseline, month 6, month 12, month 18